ArticleLiver cancer2022
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).
Open access · goldAbstract read
In one paragraph
Article in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Neoadjuvant therapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: an updated systematic review with meta-analysis.World journal of surgical oncology · 2025Pooled it
- Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2025Pooled it
- Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.Nature communications · 2026Trial
- Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial.Frontiers in immunology · 2025Trial
- Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.Frontiers in immunology · 2025Trial
- Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.Signal transduction and targeted therapy · 2023Trial
- Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.Langenbeck's archives of surgery · 2023Trial
- Novel Strategies for the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Review.Journal of gastrointestinal cancer · 2026Review
- Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.Radiation oncology (London, England) · 2026Article
- Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.Journal of advanced research · 2026Article
- Article
- Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis.Oncology letters · 2026Article
- Article
- The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques.Cancer medicine · 2026Article
- PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy.The oncologist · 2026Article
- Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study.European radiology · 2026Article
- Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.The oncologist · 2026Article
- HAIC-Based versus TACE-Based Triple Therapy with Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Propensity Score-Matched Study.Journal of hepatocellular carcinoma · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 20 institutions in 2 countries.
Juxian SunDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Rongping GuoDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xinyu BiDepartment of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Mengchao WuDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Zhaoyou TangDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Wan Yee LauDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shusen ZhengDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China.
Xuehao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jinming YuDepartment of Oncology, Clinical College of Weifang Medical University, Weifang, China.
Xiaoping ChenHepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Jia FanDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Jiahong DongDepartment of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Chang Gung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Yongjun ChenDepartment of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunfu CuiDepartment of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Chaoliu DaiDepartment of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Chihua FangDepartment of Hepatobiliary Surgery, Zhujiang Hospital, First Military Medical University, Guangzhou, China.
Shuang FengDepartment of Radiation Oncology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Zhili JiDepartment of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Weidong JiaDepartment of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Ningyang JiaDepartment of Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Gong LiDepartment of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Jing LiDepartment of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Qiu LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jiangtao LiDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lianxin LiuDepartment of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Shichun LuDepartment of Hepatobiliary Surgery, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yi LvDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Yan MengDepartment of Radiation Oncology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Zhiqiang MengDepartment of Oncology, Shanghai Medical College, Fudan University Shanghai, Shanghai, China.
Feng ShenDepartment of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jie ShiDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Huichuan SunDepartment of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Gaojun TengDepartment of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Xuying WanDepartment of Integrated Traditional Chinese and Western Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Tianfu WenDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Liqun WuDivision of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Jinglin XiaLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Mingang YingDepartment of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China.
Jian ZhaiDepartment of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Leida ZhangDepartment of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China.
Xuewen ZhangDepartment of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China.
Zhiwei ZhangDepartment of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Haiping ZhaoDepartment of Hepatobiliary and Pancreas Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Huhehot, China.
Donghai ZhengDepartment of Traditional Chinese Medicine, Beijing Weida Traditional Chinese Medicine Tumor Hospital, Beijing, China.
Xuting ZhiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Jie ZhouDepartment of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cuncai ZhouDepartment of Hepatobiliary Surgery, Jiangxi Provincial Cancer Hospital, Nanchang, China.
Jian ZhouDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Zhaochong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kangshun ZhuDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Shuqun ChengDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNFudan University · CNArmy Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSun Yat-sen University · CNBeijing Tsinghua Chang Gung Hospital · CNSichuan University · CNTongji Hospital · CNUniversity of Science and Technology of China · CNCapital Medical University · CNChina Medical University · CNChinese PLA General Hospital · CNChinese University of Hong Kong · HKFirst Affiliated Hospital of Xi'an Jiaotong University · CNFirst Affiliated Hospital Zhejiang University · CNFujian Medical University · CNHangzhou Red Cross Hospital · CNHarbin Medical University · CNInner Mongolia Medical University · CNJiangsu Province Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.
Indexed as
GuidelineHepatocellular carcinomaMultidisciplinary therapyPortal vein tumor thrombus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.